Médecine

Paramédical

Autres domaines


Suscribirse

Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy - 26/09/20

Doi : 10.1016/j.jbspin.2020.05.003 
Luca Quartuccio a, , Francesca Valent b, Enrico Pasut c, Carlo Tascini d, Salvatore De Vita a
a Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy 
b Igiene ed Epidemiologia Clinica, ASUFC, Udine, Italy 
c Service of Pharmacy, ASUFC, Udine, Italy 
d Infectious Diseases Unit, ASUFC, Udine, Italy 

Corresponding author at: Clinic of Rheumatology, ASUFC, Department of Medicine (DAME), University of Udine, Udine, Italy.Clinic of Rheumatology, ASUFC, Department of Medicine (DAME), University of UdineUdineItaly

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Highlights

This is the first report comparing the prevalence of COVID-19 in a highly vulnerable population of immunosuppressed patients with the general population.
The prevalence of COVID-19 in rheumatic patients under biologic agents or small molecules is not higher than that observed in the general population.
Patients should be informed to safely proceed with their treatment and follow the rules for self-protection to COVID-19.

El texto completo de este artículo está disponible en PDF.

Abstract

Objective

The aim of this study is to determine the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) among adult patients treated with biologic agents or small molecules for chronic inflammatory rheumatic diseases, in particular for chronic inflammatory arthritides.

Methods

To this end, a population-based study, in the province of Udine (466,700 inhabitants, with age>15 years old, Friuli Venezia Giulia region, Italy) was planned. The primary outcome was the prevalence of COVID-19 in the first two months of the outbreak. All the rheumatic patients treated with biologic agents or small molecules in the last 6 months in our province were included (N=1051).

Results

From February 29 to April 25, 2020, 4 adult patients (4/1051, i.e. 3.8/1000, 95% Confidence Interval 1.5–9.7/1000) were registered as swab test positive by PCR for COVID-19. Overall, a total of 47/1051 (4.5%) cases were tested for COVID-19 by PCR in the same period, and 15 of them due to symptoms compatible with COVID-19. In the general population, the prevalence was 937 cases/466700 (2/1000, 95% Confidence Interval 1.9–2.1/1000, P-value=0.33, chi square test), and 20,179/466,700 (4.3%) swab tests for COVID-19 were performed.

Conclusion

The risk of COVID-19 in rheumatic patients under biologic agents or small molecules does not appear different from that observed in the general population. Patients should be informed to safely proceed with their treatment and follow the rules for self-protection to COVID-19.

El texto completo de este artículo está disponible en PDF.

Keywords : Rheumatoid arthritis, Rheumatic disease, Biologic, Small molecule, Tumor necrosis factor, Coronavirus, COVID-19


Esquema


© 2020  Société française de rhumatologie. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 87 - N° 5

P. 439-443 - octobre 2020 Regresar al número
Artículo precedente Artículo precedente
  • Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020
  • Christophe Richez, René-Marc Flipo, Francis Berenbaum, Alain Cantagrel, Pascal Claudepierre, Françoise Debiais, Philippe Dieudé, Philippe Goupille, Christian Roux, Thierry Schaeverbeke, Daniel Wendling, Thao Pham, Thierry Thomas
| Artículo siguiente Artículo siguiente
  • Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA
  • Marta Arévalo, Clementina López-Medina, Mireia Moreno Martinez-Losa, Anna Moltó, Pilar Font, Eduardo Collantes-Estevez, Jordi Gratacós

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.